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In 63 jJatients with histologically jnoved gynecologie carcinoma, circulating carcino-
embryonic antigen (CEA) was determined by radioimmunoassay before and at two intervals 
after treatment. Thirty-one jmtients of 63 had CEA values over 2.5 ng. jJer milliliter 
before treatment. In general, the CEA levels were low compared to those found in 
endodennal carcinoma. The jJercentage of elevated CEA values was slightly higher in 
cases of carcinoma of the cervix and c01·pus uteri than in those of carcinoma of the ovary. 
All patients with CEA levels greater tlwn 2.5 ng. per milliliter treated by complete surgical 
resection of tumor showed a drop of CEA levels ta below 2.5 ng. per milliliter seven weeks 
after ojJeration. In contrast, jmtients with palliative therapy showed no change in CEA 
values. About half of the patients treated with a complete course of internai and externat 
radiotherajJ)' showed a drop of CEA levels ta below 2.5 ng. per milliliter, whereas the 
other patients showed fluctuating CEA values. No correlation between clinical status and 
evolution of CEA levels in these patients could be drawn at the jJresent time. The CEA test 
se ems to be of little value for the earl y diagnosis of gynecologie carcinoma but ap pears 
ta be interesting for the evaluation of therapy and the follow-up of patients with diagnosed 
cases. 
A N I M P 0 R T A N T D E V E L 0 P M E N T in tumor 
immunology has been the description of tùmor-
associated antigens, which are present in certain 
cancers and absent or present in very low quantity 
in normal tissues. Such types of antigens have been 
identified in various human tumors, including liver,t 
colon, 2 ovary,a and cervix·1 carcinoma. 
The carcinoembryonic antigen ( CEA) was orig-
inally described by Gold and Freedman2 as a glyco-
protein present exclusively in carcinoma of the di-
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gestive tract and in the digestive organs of the hu-
man fetuses of the first and second trimesters of 
gestation. By means of a sensitive radioimmuno-
assay, it was found that nanogram levels of CEA 
could be detected in the serum of patients suffering 
from colon carcinoma. 5 This observation raised a 
considerable interest with the hope that the CEA 
test could be used as a screening method for early 
diagnosis of digestive cancers. Unfortunately, when 
larger series of patients were tested, it was found 
that nonmalignant diseases like ulcerative colitis, 
cirrhosis of the liver, and branchial emphysema 
could also give rise to slightly elevated CEA val-
ues.n-u More interesting was the fact that patients 
with carcinoma derived from organs other than 
colon, including stomach, pancreas, liver, lung, and 
prostate,"-11 and even gynecologie carcinoma•-u, 1 e 
had positive CEA values. 
The purpose of the present work is to determine 
the usefulness and limitations of the CEA test in 
the diagnosis and follow-up of gynecologie cancer 
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Table I. Individual values of plasma CEA ( nanograms per milliliter) obtained before treatment in all 
patients with gynecologie cancer and in the control subjects 
CARCINOMA OF CACINOMA OF OVARIAN CONTROL$ 
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The patients with carcinoma of the cervix, the corpus uteri, and the ovary have been separated according to the 
degree of spreading with the use of the classification of the International Federation of Gynecology and Obstetrics, The 
four blood donors who had plasma CEA values higher than 5 ng, were heavy cigarette smokers. 
patients after surgical, radiotherapeutic, and chemo-
therapeutic treatments. 
Material and methods 
One hundred and eighty-nine CEA determina-
tions were performed in the plasma of 63 patients 
with histologically proved gynecologie tumors ( 10 
ml. of blood was collected in tubes containing 33 
mg. of dry ethylenediaminetetracetic acid-Ks 
[EDTA-K3]). All tests were performed in duplicate 
before treatment as well as two and seven weeks 
after the beginning of therapy. Control subjects con-
sisted of 60 apparently healthy blood bank donors 
and 11 patients with benign gynecologie dise ases ( 5 
infections and 6 ovarian cysts). The radioimmuno-
assay was performed by the method of Thomson 
and associates,S modified by Mach and co-workers.10 ' 
11 The major modification is that duplicates of 2 ml. 
of plasma instead of 5 ml. of serum are extracted 
with perchloric acid. The sensitivity of the test is 
between 1 and 2 ng. per milliliter. The reliability 
of this method was demonstrated in a recent study 
organized by the National Institute of Health, in 
which the CEA levels of 94 blood specimens obtained 
from different patients were tested simultaneously 
by 11 different laboratories. Our results showed 82 
to 90 per cent correlation with those obtained by 
seven laboratories participating in the study, includ-
ing those of S. Das, V. L. Go, P. Gold, H. Hansen, 
F. Martin, C. Todd, and N. Zamcheck. 
Results 
Individual CEA values observed before treatment 
in 63 patients with carcinoma of the cervix, corpus 
uteri, and ovary are presented in Table I. The cases 
are separated according to the degree of spreading, 
with the use of the classification of the International 
Federation of Gynecology and Obstetrics. Among 
the 63 patients studied, 20 (32 per cent) had ele-
vated CEA levels over 5 ng. per milliliter, 11 ( 17 
per cent) had borderline CEA values (2.6 to 5 ng. 
per milliliter) and 32 (51 percent) had levels be-
low the arbitrary limit of 2.5 ng. per milliliter. The 
percentage of values over 2.5 ng. per milliliter in the 
three different types of carcinoma was 53 per cent 
for patients with cervical carcinoma, 53 per cent for 
those with carcinoma of the corpus, and 36 percent 
for those with ovarian carcinoma. If the degree of 
spreading of the carcinoma of the three different 
localizations is considered, one sees that only 42 per 
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Fig. 1. Variation of plasma CEA levels (nanograms per 
milliliter) in patient with complete tumor resection. 
cent of ail patients with Stage I carcinoma had 
CEA values above 2.5 ng. per milliliter, whereas 54 
per cent of ail those with Stage II carcinoma and 
52 percent of ail those with Stages III and IV car-
cinoma had values above this limit. Only seven pa-
tients had CEA values above 15 ng. per milliliter, 
and among them three who had values over 80 ng. 
per milliliter died within six months and were found 
at autopsy to have liver metastasis. 
In the control group, all patients with benign 
gynecologie disease had CEA values below 2.5 ng. 
per milliliter. Among the 60 blood donors, four had 
levels over 5 ng. per milliliter and four had values 
between 2.6 and 5 ng. per milliliter. The four in-
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Fig. 2. Variation of plasma CEA levels (nanograms per 
milliliter) in patients treated by a complete course of 
internai and external radiotherapy. 
dividuals with values over 5 ng. per milliliter were 
found retrospectively to be heavy cigarette smokers 
(more than 20 cigarettes a day for the last ten 
years). This is in agreement with the recent obser-
vation o.f Stevens and Mackay13 and Hansen and 
colleaguesl-1 who showed that elevated CEA levels 
can be found in apparently healthy individuals with 
heavy smoking habits. 
In order to follow the effect of therapy on CEA 
leve!, the 31 patients with values over 2.5 ng. per 
milliliter were divided into three groups according 
to the type of treatment: 
Group 1 consisted of nine patients in whom com-
plete surgical resection of tumor was possible. The 
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Fig. 3. Variation of plasma CEA levels (nanograms per 
milliliter) in patients with disseminated cancer undergoing 
palliative therapy. 
tumors were four carcinomas of the cervix ( three 
Stage I and one Stage II), four of the corpus uteri 
( three Stage I and one Stage III), and one of the 
ovary (Stage I). Fig. 1 shows that seven weeks after 
surgery, the CEA levels of all the patients of this 
group had dropped below 2.5 ng. per milliliter. 
Four patients had already reached this value two 
weeks after surgery. The patient with the highest 
value in this group (50 ng. per milliliter) had 
carcinoma of the corpus uteri (Stage III). The CEA 
level clropped only to 25 ng. per milliliter two \\'eeks 
after surgery, but five weeks later it was down to 
2.5 ng. per milliliter. At the present time, twelve 
months after surgery, this patient has a CEA value 
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of 2.1 ng. per milliliter without clinical evidence of 
tumor recurrence. 
Group 2 consisted of 15 patients treated by a 
complete course of internai and external radiother-
apy. Ten patients had carcinoma of the cervix (four 
Stage II and six Stage III) and five had carcinoma 
of the corpus uteri (one Stage II and three Stage 
III). Among these patients (Fig. 2), seven who had 
relatively low CEA levels initially had levels under 
2.5 ng. per milliliter at the end of treatment, where-
as the levels of eight others had f!uctuating values. 
At the present time, no correlation between evolu-
tion of CEA levels and clinical status can be drawn. 
Group 3 consisted of seven patients with advanced 
dissemination of cancer. Two patients with cervical 
carcinoma Stage III underwent palliative radio-
thera.py, another with a corpus carcinoma infiltrat-
ing the pelvis had an incomplete tumor resection, 
the four remaining were treated by chemotherapy 
with poor clinical response for ovarian carcinoma 
(Stage III) diagnosed at explorative laparotomy. 
Fig. 3 shows that in these patients no significant 
changes in CEA levels were observed. All these pa-
tients died within six months after treatment and 
were found at autopsy to have liver metastasis. 
Comment 
The incidence of over-all gynecologie carcinoma 
with elevated CEA values reported here is compara-
ble with that observed in the limited studies already 
published on this subject. 1-0, 12 About half of the 63 
patients in the present study had CEA values over 
the arbitrary limit of 2.5 ng. per milliliter and one 
third had levels over 5 ng. per milliliter. Among the 
patients with different types of gynecologie carci-
noma, those with carcinoma of the corpus uteri and 
the cervix showed more elevated values than did 
those with carcinoma of the ovary. One interesting 
finding was that the elevated values werc not pres-
ent only in large metastatic cancers but also in sev-
era! cases of localized tu mor (Stages I and II) . 
However, in general, the percentage of elevated 
CEA levels as well as the individual CEA values 
were low in patients with gynecologie carcinoma 
compared with those observed in patients with gas-
trointestinal cancers. "-11 For comparison, in a recent 
study with the use of the sarne radioimmunoassay, 
we found 65 per cent of CEA values greater than 
5 ng. per milliliter and 33 per cent greater than 20 
ng. per milliliter in 35 patients with localized colonie 
and rectal carcinoma (Duke's Stages A and B) .17 
If one takes into account on one hand that most 
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patients with gynecologie carcinoma had relatively 
low CEA values when already clinically symptomatic 
and on the other hand that severa! nonmalignant 
conditions6-11• H, 16 and even heavy smoking13• 14 can 
give rise to slightly elevated CEA values, one should 
conclude that the CEA test is of little use for the 
early diagnosis of gynecologie carcinoma. It certainly 
should not be considered as a screening test for these 
types of cancer. 
The most interesting observation of this study is 
the decrease of CEA level to nonnal values after 
complete surgical resection of the tumor (Fig. 1). 
As suggested for other types of cancer, the post-
surgical CEA test should help to evaluate ther-
apy.5-11• 1 4-1 7 The persistence of an elevated CEA 
level in absence of an associated pathology strongly 
suggests the presence of a residual tumor. 
The changes in CEA levels during the course of 
radiotherapy are not as clear as those observed after 
surgery. Only about half of the patients show a drop 
to below 2.5 ng. per milliliter. The persistence of an 
elevated CEA even after a good clinical response 
to radiotherapy, already observed by Khoo and 
Mackay/2 is difficult to explain. It might be due to 
a residual nonproliferating tumor or to the release 
of CEA by cancer cells undergoing postactinic ne-
crosis. These patients will be followed for a longer 
period of time to determine whether the CEA level 
will drop progressively with the slow destruction of 
tumor or if persistant elevated CEA indicated the 
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this population with high risk of relapse. The fact 
of knowing the lowest postsurgical values as a CEA 
base line also helps to detect minor elevation of the 
CEA level. These arguments speak in favor of use 
of the CEA test ( every two to three months depend-
ing on the rapidity of growth of the tumor) for 
the surveillance of patients with gynecologie car-
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proved that an early warning of relapse will modify 
the therapeutic approach, the prognosis, and the 
patients' survival. 
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